Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells.

Abstract

GSCs were highly sensitive to the combination of Met and Soraf which reduced cell proliferation, increased oxidative stress, inhibited efflux pump activity and ultimately killed GSCs. We strongly believe that these results warrant further in vivo exploration.